Connecticut Wealth Management LLC Has $826,000 Stock Position in Becton, Dickinson and Company $BDX

Connecticut Wealth Management LLC lifted its position in Becton, Dickinson and Company (NYSE:BDX) by 1.9% in the first quarter, Holdings Channel.com reports. The institutional investor owned 3,608 shares of the medical instruments supplier’s stock after buying an additional 67 shares during the period. Connecticut Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $826,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in BDX. Brighton Jones LLC raised its stake in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares during the period. Hara Capital LLC raised its stake in Becton, Dickinson and Company by 26.4% during the 4th quarter. Hara Capital LLC now owns 335 shares of the medical instruments supplier’s stock worth $76,000 after buying an additional 70 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in Becton, Dickinson and Company during the 4th quarter worth $3,317,000. AXA S.A. raised its stake in Becton, Dickinson and Company by 4.4% during the 4th quarter. AXA S.A. now owns 471,120 shares of the medical instruments supplier’s stock worth $106,883,000 after buying an additional 19,734 shares during the period. Finally, Aptus Capital Advisors LLC raised its stake in Becton, Dickinson and Company by 273.6% during the 4th quarter. Aptus Capital Advisors LLC now owns 13,724 shares of the medical instruments supplier’s stock worth $3,114,000 after buying an additional 10,051 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on BDX. Barclays dropped their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 3rd. Wells Fargo & Company lifted their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Morgan Stanley lifted their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Citigroup downgraded Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and dropped their price target for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Finally, Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $211.44.

Becton, Dickinson and Company Stock Performance

BDX opened at $192.84 on Friday. The business’s 50-day moving average price is $183.07 and its two-hundred day moving average price is $194.05. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The company has a market capitalization of $55.27 billion, a price-to-earnings ratio of 34.68, a P/E/G ratio of 1.44 and a beta of 0.20. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.Becton, Dickinson and Company’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 74.82%.

Insider Activity

In other news, Director Claire Fraser sold 863 shares of the firm’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $192.30, for a total value of $165,954.90. Following the completion of the transaction, the director owned 23,143 shares in the company, valued at $4,450,398.90. This trade represents a 3.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David Shan sold 1,166 shares of the firm’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president owned 4,575 shares of the company’s stock, valued at $783,194.25. The trade was a 20.31% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,214 shares of company stock worth $579,206 in the last quarter. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.